Ribonucleic Acid (RNA) Probe Market Global Report 2026

The ribonucleic acid (RNA) probe market size has grown strongly in recent years. It will grow from $1.91 billion in 2025 to $2.08 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to growth in molecular diagnostics and gene expression research, development of fluorescent and radiolabeled probe technologies, increasing adoption of in situ hybridization techniques, expansion of cancer genomics and infectious disease testing, rising demand for high specificity nucleic acid detection methods.

The ribonucleic acid (RNA) probe market size is expected to see strong growth in the next few years. It will grow to $2.92 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to integration of AI driven probe design and sequence optimization tools, increasing demand for precision diagnostics and personalized medicine, expansion of spatial transcriptomics and single cell analysis applications, rising adoption of multiplexed and high throughput probe based assays, growth in advanced imaging and molecular detection technologies. Major trends in the forecast period include integration of fluorescent multiplex rna probe technologies for high sensitivity gene expression detection, increasing adoption of custom synthesized rna probes for precision molecular diagnostics, growing use of isothermal amplification based probe detection systems, expansion of in situ hybridization techniques for spatial transcriptomics, rising demand for enzyme labeled probes in cancer and pathogen detection workflows.

The increasing prevalence of genetic disorders is expected to drive the growth of the ribonucleic acid (RNA) probe market going forward. Genetic disorders are diseases or conditions caused by alterations or mutations in an individual's DNA, which may be inherited from parents or arise spontaneously. The prevalence of genetic disorders is increasing due to advancements in diagnostic technologies and the expansion of genetic screening programs, enabling the identification of cases that previously remained undiagnosed. Ribonucleic acid (RNA) probes support the detection of genetic disorders by specifically binding to complementary messenger RNA sequences, allowing the identification of abnormal gene expression and genetic mutations for precise molecular diagnosis. For instance, in October 2025, according to the Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, cystic fibrosis patient registrations rose from 11,148 in 2022 and 11,318 in 2023 to 11,381 in 2024, reflecting consistent year-over-year growth. Therefore, the increasing prevalence of genetic disorders is driving the growth of the ribonucleic acid (RNA) probe market.

Major companies operating in the ribonucleic acid (RNA) probe market are emphasizing the development of innovative technologies, such as high-fidelity RNA synthesis enzymes, to improve probe quality, minimize immunogenic byproducts, and enhance accuracy in molecular diagnostics and research applications. High-fidelity RNA synthesis systems are advanced molecular biology technologies designed to produce RNA molecules with greater purity and significantly lower double-stranded RNA (dsRNA) contamination, which can otherwise induce unwanted immune responses and compromise assay reliability compared to conventional RNA polymerase-based synthesis methods. For instance, in September 2024, TriLink BioTechnologies Inc., a US-based Maravai LifeSciences company, in collaboration with Alphazyme LLC, a US-based biotechnology company, introduced CleanScribe RNA Polymerase, an advanced enzyme developed to substantially enhance RNA synthesis quality. The enzyme decreases double-stranded RNA formation by up to 85% during in vitro transcription, improving the safety and performance of RNA-based applications, including RNA probe production and mRNA construct development. Furthermore, the system integrates easily into existing IVT workflows without requiring significant protocol modifications, making it well suited for both research and therapeutic RNA manufacturing pipelines. The technology also enables improved reproducibility and higher-quality RNA production, supporting more dependable downstream diagnostic and genomic applications.

In May 2024, Bruker Corporation, a US-based technology company, acquired the NanoString Technologies Inc. business for $392.6 million. Through this acquisition, Bruker sought to enhance its spatial biology and life sciences tools portfolio by incorporating NanoString’s gene expression profiling and spatial transcriptomics platforms, thereby broadening its capabilities in advanced biological research, translational science, and multi-omics discovery workflows across academic and clinical research markets. NanoString Technologies Inc. is a US-based life sciences tools company specializing in target-specific hybridization probes for the detection and quantification of ribonucleic acid (RNA).

Major companies operating in the ribonucleic acid (RNA) probe market report are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Eurofins Scientific SE, Agilent Technologies Inc., Revvity Inc., QIAGEN N.V., Bio-Techne Corporation, GenScript Biotech Corporation, Takara Bio Inc., RiboBio Co. Ltd., Bio-Synthesis Inc., Biotage AB, Biolegio B.V., Ella Biotech GmbH, Baseclick GmbH, Geno Technology Inc., Enzo Biochem Inc., LGC Biosearch Technologies, Integrated DNA Technologies (IDT)

North America was the dominating region in the ribonucleic acid (RNA) probe market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the ribonucleic acid (RNA) probe market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribonucleic acid (RNA) probe market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.